SeaStar Medical Holding Corporation announced strong survival data extending to 90 days from real-world experience with QUELIMMUNE therapy. The results are consistent with clinical trial data, showing a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. The therapy demonstrates a 50% reduction in patient mortality at 60 days compared to historical data. No device-related adverse events were reported, and the therapy is available for critically ill pediatric patients with AKI and sepsis. The SAVE Registry is collecting additional safety and effectiveness data to support broader adoption of QUELIMMUNE therapy.

Read more at GlobeNewswire: SeaStar Medical Announces Publication in Pediatric